Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ivonescimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Akeso
Deal Size : Inapplicable
Deal Type : Inapplicable
Interim Analysis Shows Ivonescimab Outperforms Pembrolizumab in NSCLC
Details : Ivonescimab, known as SMT112 in Summit’s license territories and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody.
Product Name : AK112
Product Type : Antibody
Upfront Cash : Inapplicable
April 25, 2025
Lead Product(s) : Ivonescimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Akeso
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivonescimab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Akeso
Deal Size : Inapplicable
Deal Type : Inapplicable
Ivonescimab Combo Shows PFS Superiority Over Tislelizumab in NSCLC Trial
Details : Ivonescimab, known as SMT112 in Summit’s license territories and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody.
Product Name : AK112
Product Type : Antibody
Upfront Cash : Inapplicable
April 23, 2025
Lead Product(s) : Ivonescimab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Akeso
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivonescimab,Brentuximab Vedotin
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Summit and Pfizer Collaborates to Explore Ivonescimab in Combination with Pfizer's ADCs
Details : Summit will provide AK112/SMT112 (ivonescimab), a novel global first-in-class PD-1/VEGF bi-specific immunotherapy, in combination with several of Pfizer's ADCs.
Product Name : SMT112
Product Type : Antibody
Upfront Cash : Undisclosed
February 24, 2025
Lead Product(s) : Ivonescimab,Brentuximab Vedotin
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $235.0 million
Deal Type : Private Placement
Summit Therapeutics Raises $235 Million
Details : Summit intends to use the net proceeds to advance, in part, the clinical development of SMT112 (ivonescimab) for the treatment of EFGR-mutated non-small cell lung cancer.
Product Name : SMT112
Product Type : Antibody
Upfront Cash : Undisclosed
December 09, 2024
Lead Product(s) : Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $235.0 million
Deal Type : Private Placement
Lead Product(s) : Ivonescimab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Summit Therapeutics and MD Anderson Collaborate to Accelerate Ivonescimab Development
Details : The collaboration aims to advance the clinical development of the company-lead product that targets PD-1/VEGF, SMT112 (ivonescimab) for treating patients with PD-L1-positive solid tumors.
Product Name : SMT112
Product Type : Antibody
Upfront Cash : Undisclosed
July 25, 2024
Lead Product(s) : Ivonescimab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ivonescimab Approved in China for EGFRm NSCLC Based on HARMONi-A Trial
Details : Ivonescimab, known as AK112 in China and Australia, is a novel, first-in-class, approved bispecific antibody blocking PD-1 with VEGF for treating EGFR-mutated, advanced non-squamous NSCLC.
Product Name : SMT112
Product Type : Antibody
Upfront Cash : Inapplicable
May 31, 2024
Lead Product(s) : Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ivonescimab Shows Superiority Over Pembrolizumab in NSCLC First-Line Treatment
Details : Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody inhibiting PD-1 with VEGF is being investiated for PD-L1-positive NSCLC.
Product Name : SMT112
Product Type : Antibody
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $200.0 million
Deal Type : Financing
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
Details : Summit will to advance the clinical development of SMT112 (ivonescimab), a novel, potential first-in-class investigational bispecific antibody, in non-small cell lung cancer (NSCLC).
Product Name : SMT112
Product Type : Antibody
Upfront Cash : Undisclosed
March 06, 2024
Lead Product(s) : Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $200.0 million
Deal Type : Financing
Lead Product(s) : Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SMT112 (ivonescimab) is an investigational bispecific antibody which blocks PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. It is being investigated for EGFR mutated NSCLC.
Product Name : SMT112
Product Type : Antibody
Upfront Cash : Inapplicable
September 05, 2023
Lead Product(s) : Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivonescimab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)
Details : SMT112 (ivonescimab) is a novel, potential first-in-class, investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.
Product Name : SMT112
Product Type : Antibody
Upfront Cash : Inapplicable
March 05, 2023
Lead Product(s) : Ivonescimab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable